NCT03964532 - TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Talazoparib

Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.

DRUG

Avelumab

Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.

Trial Locations (2)

20007

MedStar Georgetown University Hospital, Washington D.C.

84112

University of Utah, Huntsman Cancer Institute, Salt Lake City